Cargando…

Sofosbuvir, a Significant Paradigm Change in HCV Treatment

Nucleotide compounds like sofosbuvir, acyclovir, and tenofovir have proven to be amongst the most potent orally available antiviral treatments. These drugs exhibit high efficacy and a wide therapeutic index, with demonstrated utility in a number of chronic viral infections. The approval of Sovaldi™,...

Descripción completa

Detalles Bibliográficos
Autores principales:	McQuaid, Thomas, Savini, Carolyn, Seyedkazemi, Star
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Ltd 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542085/ https://www.ncbi.nlm.nih.gov/pubmed/26357632 http://dx.doi.org/10.14218/JCTH.2014.00041

Ejemplares similares

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
por: Kayali, Zeid, et al.
Publicado: (2014)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Hepatitis C eradication with sofosbuvir leads to significant metabolic changes
por: Morales, Amilcar L, et al.
Publicado: (2016)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Sofosbuvir improves HCV‐induced insulin resistance by blocking IRS1 degradation
por: Rey, Esther, et al.
Publicado: (2021)

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
por: Ogbuagu, Onyema, et al.
Publicado: (2018)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
por: Walker, Andreas, et al.
Publicado: (2017)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
por: Duerr, Michael, et al.
Publicado: (2019)

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients
por: Ajlan, A., et al.
Publicado: (2016)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis
por: Wang, Ying-Wen, et al.
Publicado: (2021)

Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China
por: Zhang, Hedong, et al.
Publicado: (2022)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
por: Alcazer, Vincent, et al.
Publicado: (2018)

The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir
por: Wu, Cheng-Kun, et al.
Publicado: (2022)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
por: Marascio, Nadia, et al.
Publicado: (2019)

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
por: Malespin, Miguel, et al.
Publicado: (2016)

Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
por: Buonaguro, Luigi, et al.
Publicado: (2020)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
por: Nada, Ali, et al.
Publicado: (2020)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
por: Do, Albert, et al.
Publicado: (2015)

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
por: Wei, Lai, et al.
Publicado: (2018)

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
por: Mazzitelli, Maria, et al.
Publicado: (2018)

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
por: Gilroy, Shelley, et al.
Publicado: (2017)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Changing the face of hepatitis C management – the design and development of sofosbuvir
por: Noell, Bennett C, et al.
Publicado: (2015)

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
por: Lee, Soon Kyu, et al.
Publicado: (2022)

Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis
por: Khan, Mohammad Qasim, et al.
Publicado: (2017)

Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
por: Obed, Aiman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jq4mssvrakprdc1gskjr370fis